Health Innovation Manchester is showcasing Manchester’s MedTech capabilities at AdvaMed 2016 in Minneapolis this week before heading to Boston and Chicago as part of a health innovation roadshow.
This is the first time Health Innovation Manchester has travelled to the US to highlight the city’s strengths in MedTech and Manchester’s excellence in research and health informatics.
A competitive business destination for US companies to expand their MedTech operations, Manchester is already home to American life sciences companies including Waters Corporation and Hologic.
Rowena Burns, chair of Health Innovation Manchester, said: “Our vision is to transform the health and well-being of the people of Greater Manchester by accelerating the discovery, development and delivery of new treatments and processes.
“To help us achieve this it’s important that Greater Manchester showcases its world-class assets in healthcare, clinical research, innovation and academia to a global audience, so our presence at AdvaMed is a great opportunity to not only understand the latest sector trends and thinking but to build new contacts and networks.
“We hope this will lead to fresh collaboration and bring inward investment to the city region with the ultimate goal of providing better healthcare outcomes for the people of Greater Manchester and beyond.”
The aim of the visit is to seek international innovation partners to address the specific unmet healthcare needs of the 2.7 million people in Greater Manchester and beyond. This affords unique opportunities to test and adopt new innovation directly into the National Health Service through local commissioning.
Tim Newns, chief executive officer, MIDAS, Manchester’s inward investment agency, added: “As Manchester is the only city in the UK to take control of its £6bn health and social care budget, businesses will soon find it easier than ever before to engage with Manchester’s world-class health sector and will benefit from being able to move much more quickly from the lab to having an impact on people in the UK, and ultimately around the world.
“Over 200 biomedical companies are located in Greater Manchester, contributing £4bn to the local economy and it is the most invested in city in the UK outside London. The US is Manchester’s number one country for foreign direct investment and we are always seeking opportunities to forge R&D collaborations and welcome companies looking to get a foothold in the UK.
“Following the EU Referendum, this roadshow is the perfect platform for Health Innovation Manchester to connect with a number of industry, academic and clinical institutions along with investors and potential customers outside Europe. Manchester has a positive outlook post-Brexit and we look forward to engaging with potential international innovation partners.
“Greater Manchester is incredibly well connected, flying to over 200 international destinations. We already fly direct to 11 cities in the US including Chicago, Boston, Washington and New York, making it the perfect location for American companies to set up operations.”